The Pharming Group proclaims its intention to nominate three non-executive administrators to the Board of Administrators
TO SUFFER, Netherlands, March 23, 2021 / PRNewswire / – Pharming Group NV (“Pharming” or “the Firm”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) proclaims its intention to be nominated Steven Baert, Leon Kruimer and Jabine van der Meijs as non-executive administrators of the board of administrators. Their official appointments might be confirmed by the corporate’s basic assembly held on Might 19, 2021. Till that second Steven Baert, Leon Kruimer and Jabine van der Meijs will maintain supervisory roles on the Board of Administrators. Steven, Leon and Jabine will change Jürgen Ernst who entered November 2020 and Aad de Winter and Barrie WardEach can’t be re-elected as a result of most time period of workplace for non-executive administrators beneath the Dutch Company Governance Code.
Paul Sekhri, Chairman of the Board of Administrators, commented:
“We’re very completely satisfied concerning the nomination Steven Baert, Leon Kruimer and Jabine van der Meijs as non-executive administrators of the board of administrators. Her in depth international expertise in finance, strategic and organizational growth in multinational organizations and numerous industries will complement and additional strengthen the present experience and variety of our Board of Administrators as Pharming continues its bold development technique following a latest Nasdaq secondary itemizing within the US implements. “
Steven Baert has been Chief Folks Officer and member of the Govt Committee of Novartis AG (SWX: NOVN) since 2014. Steven joined Novartis in 2006 and has held various management roles throughout the firm together with Head of Human Sources, World Features, Switzerland, Head of Human Sources for Rising Markets, Head of Human Sources, United States and Canadaand World Head, Human Sources, Novartis Oncology. Previous to becoming a member of Novartis, Steven held senior HR positions at Bristol-Myers Squibb Co. and Unilever.
Steven holds a Masters of Enterprise Administration from Vlerick Enterprise Faculty, Ghent; a Grasp of Legal guidelines from the Katholieke Universiteit Leuven and a Bachelor of Legal guidelines from the Katholieke Universiteit Brussels. Steven can be a member of the Board of the WeSeeHope USA, a charity centered on empowering youngsters remoted from poverty Africa.
Leon Kruimer has over 30 years of company finance, planning and technique expertise, together with 20 years in senior positions in personal and publicly traded biotechnology firms. Leonard was CFO of Crucell NV from 1997 to 2011. Previous to Crucell, he was Managing Director of Europe TIP Trailer, a GE Capital firm. He was additionally a marketing consultant at McKinsey & Co and a chartered accountant at Value Waterhouse & Firm. new York.
Leon is at present the CEO of Swedish BioInvent Worldwide AB (BINV.ST). He’s additionally a board member of the 2 Zealand Pharma A / S in Copenhagen and Oncolytics Inc (NASDAQ: ONCY) primarily based in Calgary. He’s director of AI World Investments (Netherlands) PCC Ltd. and is a member of the Funding Advisory Council of Karmijn Kapitaal. Leonard holds a Grasp of Enterprise Administration from Harvard Enterprise Faculty and is an auditor in New York State.
As a monetary skilled Leon Kruimer must be profitable Aad de Winter as chairman of the audit committee, topic to his appointment as non-executive director
Jabine van der Meijs
Jabine was Govt Vice President & CFO of the Royal Schiphol Group from 2017 to the tip of 2017 March 2021. Jabine beforehand labored for the Royal Dutch Shell Group (ENXTAM: RDSA) for 25 years in primarily monetary administration positions, but in addition in HR and technique positions in The Netherlands, Scotland, England, Brunei and Australia. In her final place at Shell, she was VP Finance Initiatives for Shell’s challenge and expertise enterprise.
Jabine is at present a member of the Supervisory Board of Kendrion NV (ENXTAM: KENDR), the place she serves because the Chair of the Audit Committee. She is a member of the board of administrators of Koole Terminals Holding BV, the place she chairs the Folks & Remuneration Committee, and was not too long ago appointed to the board of administrators of Grundfos Holding, a privately owned Danish firm.
Jabine beforehand served as a non-executive director on numerous boards of administrators, together with Aeroports de Paris, France) (ENXTPA: ADP) and Brisbane Airport Company (Australia). Jabine holds a Masters of Science (Pharmacy) and a PhD in Pharmacy (Pharm D) from the College of Utrechtand she or he accomplished her skilled accounting diploma within the UK from the Chartered Institute of Administration Accountants (ACMA).
About Pharming Group NV
Pharming Group NV is a world commercial-stage biopharmaceutical firm growing revolutionary protein alternative therapies and precision medicine for the remedy of uncommon illnesses and unmet medical wants.
The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that downregulates the complement cascade to regulate irritation in affected tissues.
Our flagship product, RUCONEST®, is the primary and solely plasma-free rhC1INH protein alternative remedy. It’s permitted for the remedy of acute hereditary angioedema (HAE). We market RUCONEST® in The US, the European Union and the United Kingdom via our personal gross sales and advertising group and the remainder of the world via our gross sales community.
As well as, we’re investigating the medical efficacy of rhC1INH within the remedy of different indications, together with preeclampsia, acute kidney damage, and extreme pneumonia as a consequence of COVID-19 infections.
We’re additionally investigating our oral precision drugs leniolisib (a phosphoinositide-3-kinase-delta or PI3K-delta inhibitor) for the remedy of activated PI3K-delta syndrome (APDS) in a registry that enables a section 2/3 research in The US and Europe.
As well as, we’re leveraging our transgenic manufacturing expertise to develop subsequent technology protein alternative therapies, notably for Pompe illness, which is at present in preclinical growth.
This press launch accommodates forward-looking statements, together with the timing and progress of Pharming’s preclinical and medical trials of its product candidates, Pharming’s medical and industrial prospects, and Pharming’s skill to fulfill the challenges posed by the COVID-19. Pandemic to Conduct Revealed Pharming’s statements relating to projected working capital wants and liquidity assets are topic to various dangers, uncertainties, and assumptions together with, however not restricted to, the scope, progress, and extent of medical trials and impacts Pharming for the price thereof; in addition to medical, scientific, regulatory and technical developments. Given these dangers and uncertainties, in addition to different dangers and uncertainties described in Pharming’s 2019 Annual Report and its report for the previous 9 months September 30, 2020The occasions and circumstances mentioned in such forward-looking statements could not materialize, and Pharming’s precise outcomes might differ materially and adversely from these anticipated or implied. All forward-looking statements communicate solely as of the date of this press launch and are primarily based on info accessible to Pharming as of the date of this press launch.
This press launch pertains to the disclosure of knowledge that qualifies or could qualify as inside info throughout the which means of Article 7 (1) of the EU Market Abuse Regulation.
For extra public info, contact:
Pharming Group, Leiden, The Netherlands
Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton, Investor Relations Supervisor: T: +31 71 524 7400, E: [email protected]
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/.Alex Shaw/.Mary Whittow
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, Netherlands
T: +31 6 53 81 64 27
E: [email protected]
SOURCE Pharming Group NV